Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)
China flag China · Delayed Price · Currency is CNY
5.25
-0.19 (-3.49%)
Sep 10, 2026, 12:44 PM CST

SHE:300039 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,0091,1491,4711,5911,1171,099
Other Revenue
2.393.331.93.032.251.29
1,0111,1531,4731,5941,1191,101
Revenue Growth
-19.05%-21.76%-7.57%42.47%1.66%21.21%
Cost of Revenue
199.96222.21272.96311.82247.85234.1
Gross Profit
810.97930.451,2001,282871866.48
Selling, General & Admin
480.43562.71727.1858.13612.86652.66
Research & Development
73.7988.2799.7995.8752.9779.32
Other Operating Expenses
13.3617.6122.7623.9216.9211.5
Operating Expenses
570.98666.97845.34972.48689.51747.13
Operating Income
240263.48355.02309.75181.49119.35
Interest Expense
-0.05-0.1-0.04---0.15
Interest & Investment Income
44.3361.5564.560.8742.6644.77
Other Non Operating Income (Expenses)
19.35-0.06-0.11-0.57-0.16-0.03
EBT Excluding Unusual Items
303.62324.87419.37370.05224163.94
Impairment of Goodwill
----9.04-4.75-4.71
Gain (Loss) on Sale of Investments
-10.25-10.231.1-4.54-6.591.8
Gain (Loss) on Sale of Assets
-0.20.04-0.26-0.21-0.17-0.22
Asset Writedown
-0.33-0.14-0.62-0.1--
Other Unusual Items
6.177.5114.5927.3813.718.84
Pretax Income
299.01322.05434.18383.53226.19169.65
Income Tax Expense
40.9744.0559.2756.6336.1129.54
Earnings From Continuing Operations
258.04278374.91326.9190.08140.11
Minority Interest in Earnings
0.530.580.670.970.720
Net Income
258.56278.58375.58327.87190.8140.11
Net Income to Common
258.56278.58375.58327.87190.8140.11
Net Income Growth
-27.25%-25.82%14.55%71.84%36.18%32.03%
Shares Outstanding (Basic)
1,0461,0461,0461,0461,0461,046
Shares Outstanding (Diluted)
1,0461,0461,0461,0461,0461,046
Shares Change
0.00%0.02%0.00%-0.02%0.01%0.04%
EPS (Basic)
0.250.270.360.310.180.13
EPS (Diluted)
0.250.270.360.310.180.13
EPS Growth
-27.25%-25.84%14.54%71.88%36.17%31.97%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
161.7203.7138.43353.59344.883.53
Free Cash Flow Per Share
0.150.200.130.340.330.08
Dividend Per Share
0.1000.1300.1000.1000.0600.050
Dividend Growth
-23.08%30.00%0%66.67%20.00%66.67%
Gross Margin
80.22%80.72%81.47%80.44%77.85%78.73%
Operating Margin
23.74%22.86%24.10%19.43%16.22%10.84%
Profit Margin
25.58%24.17%25.49%20.57%17.05%12.73%
Free Cash Flow Margin
16.00%17.67%9.40%22.18%30.82%7.59%
EBITDA
274.95296.97391.07347.28213.2153.21
EBITDA Margin
27.20%25.76%26.54%21.79%19.05%13.92%
D&A For EBITDA
34.9633.4936.0537.5331.7133.86
EBIT
240263.48355.02309.75181.49119.35
EBIT Margin
23.74%22.86%24.10%19.43%16.22%10.84%
Effective Tax Rate
13.70%13.68%13.65%14.77%15.96%17.41%
Revenue as Reported
548.011,1531,4731,5941,1191,101
Advertising Expenses
-----11.24